BioTherapeutics invited to present at the Governor’s Forum on Bio and Big Data
BLACKSBURG, VA: Apr. 27, 2015 - The Biotherapeutics (BTI) team traveled to Chantilly, VA, to present at the Governor’s Forum on Bio and Big Data as part of the THRiVE conference organized by Virginia BIO. In this event, leading Virginia companies presented cutting edge work, identified needs, and revealed tremendous opportunities ahead, creating new relationships across industries with the goal of advancing the state of Virginia as a bioscience and healthcare key player in the biotech and Pharma fields. Dr. Bassaganya-Riera presented the latest BTI’s technology to accelerate the path to cures for widespread and debilitating human diseases.
“BTI leverages the untapped capabilities of modeling and simulation to accelerate the development of new disruptive therapeutics.” Said Dr. Bassaganya-Riera, President and CEO of BTI. “BTI’s integrated pipeline combines computational modeling with pre-clinical and clinical validation studies to develop new classes of safer and more effective drugs for Inflammatory Bowel Disease, Type 2 Diabetes, Influenza, and Rheumatoid Arthtitis” –Dr. Bassaganya-Riera added.
Jeffrey M. Gallagher, CEO of Virginia BIO, recently visited the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) at the Virginia Bioinformatics Institute at Virginia Tech, and Biotherapeutics to observe first-hand how such efficient combination of computational modeling and experimental validation is used to develop new drug candidates and advancing them into the market. During the THRiVE conference, the Virginia Bioinformatics Institute received an award for its pioneering work in modeling and simulation that accelerates medical and health research in Virginia and worldwide.
The Virginia Bioinformatics Institute at Virginia Tech has also released a press note about the Governor’s Forum on Bio and Big Data, highlighting the contribution of Dr. Bassaganya-Riera on the development of transdisciplinary approaches to accelerate drug development. Read it here.
About Biotherapeutics Inc.
A pre-clinical stage, small-molecule company advancing therapeutics for inflammation and diabetes. BioTherapeutics was established in 2008 with the mission to develop safer and more effective treatments for human diseases. The company holds numerous patents on innovative mechanisms of anti-inflammatory and anti-diabetic action. The technology was validated with numerous pre-clinical studies resulting in 12 peer-reviewed publications elucidating a novel pathway and showing the compounds to be both safe and effective. Biotherapeutics is expanding rapidly to support additional pre-clinical studies with the goal of submitting an IND application to the Food and Drug Administration.